60 Degrees Pharmaceuticals, Inc. Warrant - on 60 Degrees Ph SXTPW 深 滬
已收盤 02-06 16:00:00 美东时间
0.0683
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.0683
- 總市值 0
- 52周最高 0.156
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.02
- 委 比 12.52%
- 總股本 --
- 歷史最高 1.6777
- 量 比 0
- 振 幅 0.00%
- 歷史最低 0.0101
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多60 Degrees Pharma Launches B-FREE Study, First-Ever Trial for Chronic Babesiosis Treatment
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today the name
2025-10-09 19:18
60 Degrees Pharma Signs Clinical Trial Agreement With Icahn School Of Medicine At Mount Sinai In New York City As Central Site For Phase II Clinical Study Of Tafenoquine In Treating Chronic Babesiosis
90-day trial measuring change in general fatigue in chronic babesiosis patientsEnrollment expected to commence Q4 2025 and to be completed by Q2 2026Site has clinical expertise in infectious disease trials and access to
2025-08-19 20:56
60 Degrees Pharmaceuticals Announces The Company Will Conduct A Gap Analysis Of Its Existing Data Prior To Submitting A Minor Use Minor Species Designation Request To The U.S. FDA For Tafenoquine For The Treatment Of Acute Canine Babesiosis
Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosisWASHINGTON, July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)))
2025-07-15 04:03
60 Degrees Pharmaceuticals Launches New 8-Count Bottle Format Of ARAKODA
New 8-count bottles now available through major retail pharmaciesARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malariaWASHINGTON, June 04, 2025 (GLOBE
2025-06-04 20:59
60 Degrees Pharma Regains Compliance With Nasdaq Listing Requirements
60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP, SXTPW)))) ("60P" or the "Company"), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it
2024-01-16 20:59
WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit
JERSEY CITY, N.J., July 12, 2023 /PRNewswire/ -- WallachBeth Capital LLC, a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmace...
2023-07-13 01:45
60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering
WASHINGTON, July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.,...
2023-07-13 00:29
